MYC in cancer: from undruggable target to clinical trials
Top Cited Papers
Open Access
- 19 February 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 24 (6) , 445-457
Abstract
MYC is among the most infamous oncogenes in cancer. A notable feature that distinguishes it from other common oncogenes is that its deregulation is not usually due to direct mutation, but instead to its relentless activation by other oncogenic lesions. These signalling pathways funnel through MYC to execute the transcriptional programmes that eventually lead to the uncontrolled proliferation of cancer cells. Indeed, deregulated MYC activity may be linked to most — if not all — human cancers. Despite this unquestionable role of MYC in tumour development and maintenance, no MYC inhibitor has yet been approved for clinical use. The main reason is that MYC has long fallen into the category of ‘undruggable’ or ‘difficult-to-drug’ targets, mainly because of its intrinsically disordered structure, which is not amenable to traditional drug development strategies. However, in recent years, attempts to develop MYC inhibitors have multiplied, and the first clinical trials have been testing their efficacy in patients. We are finally reaching the point at which its inhibition seems clinically viable. This Review provides an overview of the various strategies to inhibit MYC, focusing on the most recently described inhibitors and those that have reached clinical trials.Keywords
This publication has 143 references indexed in Scilit:
- Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc ProteinAdvanced Science, 2024
- Bacterial delivery of therapeutic proteins to the nuclei of cancer cellsBiotechnology and Bioengineering, 2023
- Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c‐Myc G‐Quadruplex Stabilizers to Suppress c‐Myc Transcription and Myeloma GrowthMolecular Informatics, 2022
- A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing TumorsAdvanced Science, 2022
- Inhibition of Myc transcriptional activity by a mini‐protein based upon Mxd1FEBS Letters, 2020
- G-Quadruplex DNA and RNA2019
- Inhibition of MYC attenuates tumor cell self‐renewal and promotes senescence in SMARCB1‐deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivoInternational Journal of Cancer, 2019
- Oligonucleotide N3′→P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic AgentsChemistry & Biodiversity, 2010
- The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivativesApplied Microbiology and Biotechnology, 2006
- Advanced c‐myc antisense (AVI‐4126)‐eluting phosphorylcholine‐coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis modelCatheterization and Cardiovascular Interventions, 2004